Elite Pharmaceuticals has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for a generic version of an immediate release CNS stimulant.    The ANDA represents the first filing for a product co-developed with SunGen Pharma under their Development and License Agreement. According to IMS Health data the branded product and its equivalents had total U.S. sales of more than $400 million for the twelve months ending September 30, 2017.   U...